

**Over expression of HER2/neu in female ductal carcinoma:  
Pure invasive versus invasive with in situ component**

Mohamed Salah Abdelhamid<sup>1</sup>, Ahmed Mohamed Sadat<sup>1</sup>, Mohamed Salah Abdelbasset<sup>1</sup>,  
Amr Mohamed Aly Mohamed<sup>1</sup>, Hesham Ahmed Abdel Wahab Nafady<sup>1</sup>,  
Khald Mohamed Shawky<sup>1</sup>, Solafa Amin Abdelaziz<sup>2</sup>, Lobna Omar El Farouk Abd Elsalam<sup>2</sup>,  
Mahmoud Ahmed Negida<sup>2</sup>, Reham Shehab El Nemr Esmail<sup>3</sup>, Adel Morad Abdellah<sup>4</sup>,  
Ahmed Zaki Gharib<sup>4</sup>

Abstract:

**Aims:** We are trying to understand the role of HER 2 neu in tumor progression. **Study design:** Prospective study.  
**Place and duration:** Conducted at Bani Swif and Kasr AL Aini university hospitals between May 2013 and May 2014.  
**Methodology:** 32 patients were enrolled in the study. The specimens were obtained surgically. Expression of HER-2-neu receptors done aided with Dako Code No. A0485. **Results:** In the study there were 15 cases with pure invasive carcinoma and 17 cases with in situ component, there were more positive cases (59%) with HER-2-neu in the invasive associated with in situ group than those in the pure invasive group (20%), this was statistically significant ( $P < 0.016$ ). **Conclusion:** In conclusion, it may be assumed that during cells of the in situ component are acquiring invasiveness, they partly lose Her-2-neu over expression. The high percent of positive HER-2-neu in cases associated with in situ component point an arrow with question mark towards possible changes in the tumor cell biology or the actual cell line of the in situ and the invasive components.

مكان وتاريخ النشر:

**Journal of Surgery**  
2014; 2(6): 105-108